Trial Profile
A Single Arm Multiple Dose Study to Assess the Efficacy and Safety of ANB019 in Subjects With Generalized Pustular Psoriasis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 May 2023
Price :
$35
*
At a glance
- Drugs Imsidolimab (Primary) ; Imsidolimab (Primary)
- Indications Generalised pustular psoriasis
- Focus Therapeutic Use
- Acronyms GALLOP
- Sponsors AnaptysBio
- 02 May 2023 Primary endpoint has been met. (Percentage of Participants Achieving Clinical Response on the Clinical Global Impression (CGI) Scale)
- 02 May 2023 Results published in the Media Release
- 30 Apr 2023 Results published in the British Journal of Dermatology